FGFR inhibitor and application thereof
US11365196B2 · kind B2 · utility
1Cited by
1References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 27, 2018 |
| Grant date | Jun 21, 2022 |
| Priority date | — |
| Expiry date | Oct 17, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
An azatricyclic compound (as represented by Formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases are provided. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.